AzTrials
AzTrials

HypertensionNCT00909038

Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study

An observational study of Hypertension, run by Boehringer Ingelheim at 915 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

It is a national, retrospective , observational study in hypertensive patients treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg. The primary objective is to assess the control rate (systolic and diastolic blood pressure). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hypertension
How many people
2,411 participants
Where
915 sitesFrance
Study dates
May 2009to Nov 2009
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: 3440

Who may be able to join

  • Hypertensives
  • Treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg

Who cannot join

  • Treated with the combination less than 8 weeks

Trial locations and contacts

915 sites in 1 country.

300 sites in 1 country

France300 sites

  • Boehringer Ingelheim Investigator site 1

    Ablon-sur-Seine

  • Boehringer Ingelheim Investigator site 2

    Achenheim

  • Boehringer Ingelheim Investigator site 3

    Afa

  • Boehringer Ingelheim Investigator site 4

    Aiguillon

  • Boehringer Ingelheim Investigator site 5

    Aire-sur-l'Adour

  • Boehringer Ingelheim Investigator site 6

    Aix-en-Othe

  • Boehringer Ingelheim Investigator site 7

    Aix-en-Provence

  • Boehringer Ingelheim Investigator site 8

    Aix-en-Provence

  • Boehringer Ingelheim Investigator site 9

    Aix-les-Bains

  • Boehringer Ingelheim Investigator site 10

    Ajaccio

  • Boehringer Ingelheim Investigator site 11

    Ajaccio

  • Boehringer Ingelheim Investigator site 12

    Amagne

  • Boehringer Ingelheim Investigator site 13

    Amiens

  • Boehringer Ingelheim Investigator site 14

    Amiens

  • Boehringer Ingelheim Investigator site 15

    Andard

  • Boehringer Ingelheim Investigator site 16

    Angers

  • Boehringer Ingelheim Investigator site 17

    Angoulême

  • Boehringer Ingelheim Investigator site 18

    Angoulême

  • Boehringer Ingelheim Investigator site 19

    Angoulême

  • Boehringer Ingelheim Investigator site 20

    Annecy

  • Boehringer Ingelheim Investigator site 21

    Annecy

  • Boehringer Ingelheim Investigator site 22

    Annemasse

  • Boehringer Ingelheim Investigator site 23

    Annonay

  • Boehringer Ingelheim Investigator site 24

    Annonay

  • Boehringer Ingelheim Investigator site 25

    Antibes

  • Boehringer Ingelheim Investigator site 26

    Antony

  • Boehringer Ingelheim Investigator site 27

    Anvin

  • Boehringer Ingelheim Investigator site 28

    Anzin

  • Boehringer Ingelheim Investigator site 29

    Appoigny

  • Boehringer Ingelheim Investigator site 30

    Ardentes

  • Boehringer Ingelheim Investigator site 31

    Argenteuil

  • Boehringer Ingelheim Investigator site 32

    Arles

  • Boehringer Ingelheim Investigator site 33

    Arques-la-Bataille

  • Boehringer Ingelheim Investigator site 34

    Arradon

  • Boehringer Ingelheim Investigator site 35

    Ars

  • Boehringer Ingelheim Investigator site 36

    Arsac

  • Boehringer Ingelheim Investigator site 37

    Artigues-près-Bordeaux

  • Boehringer Ingelheim Investigator site 38

    Asnières-sur-Seine

  • Boehringer Ingelheim Investigator site 39

    Asson

  • Boehringer Ingelheim Investigator site 40

    Aubervilliers

  • Boehringer Ingelheim Investigator site 41

    Auch

  • Boehringer Ingelheim Investigator site 42

    Augny

  • Boehringer Ingelheim Investigator site 43

    Aulnay-sous-Bois

  • Boehringer Ingelheim Investigator site 44

    Aulnay-sous-Bois

  • Boehringer Ingelheim Investigator site 45

    Aumetz

  • Boehringer Ingelheim Investigator site 46

    Auxerre

  • Boehringer Ingelheim Investigator site 47

    Auzon

  • Boehringer Ingelheim Investigator site 48

    Avallon

  • Boehringer Ingelheim Investigator site 49

    Bagneux

  • Boehringer Ingelheim Investigator site 50

    Bagnols-sur-Cèze

  • Boehringer Ingelheim Investigator site 51

    Baillet-en-France

  • Boehringer Ingelheim Investigator site 52

    Bailleul

  • Boehringer Ingelheim Investigator site 53

    Barbezieux-Saint-Hilaire

  • Boehringer Ingelheim Investigator site 54

    Barbezieux-Saint-Hilaire

  • Boehringer Ingelheim Investigator site 55

    Bassillac

  • Boehringer Ingelheim Investigator site 56

    Bassussarry

  • Boehringer Ingelheim Investigator site 57

    Bauvin

  • Boehringer Ingelheim Investigator site 58

    Bayeux

  • Boehringer Ingelheim Investigator site 59

    Beaumont-sur-Lèze

  • Boehringer Ingelheim Investigator site 60

    Beauvais

  • Boehringer Ingelheim Investigator site 61

    Bélâbre

  • Boehringer Ingelheim Investigator site 62

    Belley

  • Boehringer Ingelheim Investigator site 63

    Benfeld

  • Boehringer Ingelheim Investigator site 64

    Bergerac

  • Boehringer Ingelheim Investigator site 65

    Bergues

  • Boehringer Ingelheim Investigator site 66

    Bersée

  • Boehringer Ingelheim Investigator site 67

    Béthisy-Saint-Pierre

  • Boehringer Ingelheim Investigator site 68

    Béziers

  • Boehringer Ingelheim Investigator site 69

    Biarritz

  • Boehringer Ingelheim Investigator site 70

    Biganos

  • Boehringer Ingelheim Investigator site 71

    Biganos

  • Boehringer Ingelheim Investigator site 72

    Biganos

  • Boehringer Ingelheim Investigator site 73

    Billère

  • Boehringer Ingelheim Investigator site 74

    Billère

  • Boehringer Ingelheim Investigator site 75

    Blangy-sur-Bresle

  • Boehringer Ingelheim Investigator site 76

    Blanquefort

  • Boehringer Ingelheim Investigator site 77

    Blaye

  • Boehringer Ingelheim Investigator site 78

    Bleriot

  • Boehringer Ingelheim Investigator site 79

    Blois

  • Boehringer Ingelheim Investigator site 80

    Blotzheim

  • Boehringer Ingelheim Investigator site 81

    Bohain-en-Vermandois

  • Boehringer Ingelheim Investigator site 82

    Bois-Colombes

  • Boehringer Ingelheim Investigator site 83

    Bois-Colombes

  • Boehringer Ingelheim Investigator site 84

    Boiscommun

  • Boehringer Ingelheim Investigator site 85

    Bondoufle

  • Boehringer Ingelheim Investigator site 86

    Bondoufle

  • Boehringer Ingelheim Investigator site 87

    Bondues

  • Boehringer Ingelheim Investigator site 88

    Boos

  • Boehringer Ingelheim Investigator site 89

    Boos

  • Boehringer Ingelheim Investigator site 90

    Bordeaux

  • Boehringer Ingelheim Investigator site 91

    Bordeaux

  • Boehringer Ingelheim Investigator site 92

    Bordeaux

  • Boehringer Ingelheim Investigator site 93

    Bordeaux

  • Boehringer Ingelheim Investigator site 94

    Bouilly

  • Boehringer Ingelheim Investigator site 95

    Boulogne-Billancourt

  • Boehringer Ingelheim Investigator site 96

    Bourg-la-Reine

  • Boehringer Ingelheim Investigator site 97

    Bourron-Marlotte

  • Boehringer Ingelheim Investigator site 98

    Bourth

  • Boehringer Ingelheim Investigator site 99

    Braine

  • Boehringer Ingelheim Investigator site 100

    Brest

  • Boehringer Ingelheim Investigator site 101

    Brest

  • Boehringer Ingelheim Investigator site 102

    Brest

  • Boehringer Ingelheim Investigator site 103

    Brest

  • Boehringer Ingelheim Investigator site 104

    Brest

  • Boehringer Ingelheim Investigator site 105

    Bretenoux

  • Boehringer Ingelheim Investigator site 107

    Breteuil

  • Boehringer Ingelheim Investigator site 106

    Breteuil

  • Boehringer Ingelheim Investigator site 108

    Bretignolles-sur-Mer

  • Boehringer Ingelheim Investigator site 109

    Bretteville-l'Orgueilleuse

  • Boehringer Ingelheim Investigator site 110

    Brie

  • Boehringer Ingelheim Investigator site 111

    Brienne-le-Château

  • Boehringer Ingelheim Investigator site 112

    Briouze

  • Boehringer Ingelheim Investigator site 113

    Bron

  • Boehringer Ingelheim Investigator site 114

    Bruère-Allichamps

  • Boehringer Ingelheim Investigator site 115

    Bruges

  • Boehringer Ingelheim Investigator site 116

    Brunehamel

  • Boehringer Ingelheim Investigator site 117

    Buchy

  • Boehringer Ingelheim Investigator site 118

    Bulgnéville

  • Boehringer Ingelheim Investigator site 119

    Bulgnéville

  • Boehringer Ingelheim Investigator site 120

    Cabanac-et-Villagrains

  • Boehringer Ingelheim Investigator site 121

    Cabannes

  • Boehringer Ingelheim Investigator site 122

    Cabestany

  • Boehringer Ingelheim Investigator site 123

    Caen

  • Boehringer Ingelheim Investigator site 124

    Cagnes-sur-Mer

  • Boehringer Ingelheim Investigator site 125

    Cagnes-sur-Mer

  • Boehringer Ingelheim Investigator site 126

    Cagnes-sur-Mer

  • Boehringer Ingelheim Investigator site 127

    Callac de Bretagne

  • Boehringer Ingelheim Investigator site 128

    Callac de Bretagne

  • Boehringer Ingelheim Investigator site 129

    Cancon

  • Boehringer Ingelheim Investigator site 130

    Canéjan

  • Boehringer Ingelheim Investigator site 131

    Cannes

  • Boehringer Ingelheim Investigator site 132

    Cannes

  • Boehringer Ingelheim Investigator site 133

    Cannes

  • Boehringer Ingelheim Investigator site 134

    Cany-Barville

  • Boehringer Ingelheim Investigator site 135

    Capdenac-Gare

  • Boehringer Ingelheim Investigator site 136

    Capdenac-Gare

  • Boehringer Ingelheim Investigator site 137

    Carbon-Blanc

  • Boehringer Ingelheim Investigator site 138

    Carcassonne

  • Boehringer Ingelheim Investigator site 139

    Carcassonne

  • Boehringer Ingelheim Investigator site 140

    Carcassonne

  • Boehringer Ingelheim Investigator site 141

    Carhaix-Plouguer

  • Boehringer Ingelheim Investigator site 142

    Carpentras

  • Boehringer Ingelheim Investigator site 143

    Carvin

  • Boehringer Ingelheim Investigator site 144

    Cassis

  • Boehringer Ingelheim Investigator site 145

    Castanet-Tolosan

  • Boehringer Ingelheim Investigator site 146

    Castelnau-le-Lez

  • Boehringer Ingelheim Investigator site 147

    Castelsarrasin

  • Boehringer Ingelheim Investigator site 148

    Castelsarrasin

  • Boehringer Ingelheim Investigator site 149

    Castets

  • Boehringer Ingelheim Investigator site 150

    Castets-en-Dorthe

  • Boehringer Ingelheim Investigator site 151

    Cavalaire-sur-Mer

  • Boehringer Ingelheim Investigator site 152

    Cepoy

  • Boehringer Ingelheim Investigator site 153

    Cergy

  • Boehringer Ingelheim Investigator site 154

    Cérilly

  • Boehringer Ingelheim Investigator site 155

    Cernay

  • Boehringer Ingelheim Investigator site 156

    Châbons

  • Boehringer Ingelheim Investigator site 157

    Chalais

  • Boehringer Ingelheim Investigator site 158

    Chambray-lès-Tours

  • Boehringer Ingelheim Investigator site 159

    Champs-sur-Marne

  • Boehringer Ingelheim Investigator site 160

    Chantilly

  • Boehringer Ingelheim Investigator site 161

    Chaource

  • Boehringer Ingelheim Investigator site 162

    Charleville-Mézières

  • Boehringer Ingelheim Investigator site 163

    Charleville-Mézières

  • Boehringer Ingelheim Investigator site 164

    Chassieu

  • Boehringer Ingelheim Investigator site 165

    Château-Chinon(Ville)

  • Boehringer Ingelheim Investigator site 166

    Château-d'Olonne

  • Boehringer Ingelheim Investigator site 167

    Château-Renault

  • Boehringer Ingelheim Investigator site 168

    Château-Thébaud

  • Boehringer Ingelheim Investigator site 169

    Châteaubernard

  • Boehringer Ingelheim Investigator site 170

    Châteaubriant

  • Boehringer Ingelheim Investigator site 171

    Chateauneuf Ille Vilaine

  • Boehringer Ingelheim Investigator site 172

    Châteauroux

  • Boehringer Ingelheim Investigator site 173

    Châtenay-Malabry

  • Boehringer Ingelheim Investigator site 174

    Châtillon-Coligny

  • Boehringer Ingelheim Investigator site 175

    Châtillon-sur-Seine

  • Boehringer Ingelheim Investigator site 176

    Chaumont

  • Boehringer Ingelheim Investigator site 177

    Chauvigny

  • Boehringer Ingelheim Investigator site 178

    Chauvigny

  • Boehringer Ingelheim Investigator site 179

    Chauvigny

  • Boehringer Ingelheim Investigator site 180

    Chelles

  • Boehringer Ingelheim Investigator site 181

    Cherves-Richemont

  • Boehringer Ingelheim Investigator site 182

    Chinon

  • Boehringer Ingelheim Investigator site 183

    Claira

  • Boehringer Ingelheim Investigator site 184

    Clamart

  • Boehringer Ingelheim Investigator site 185

    Claye-Souilly

  • Boehringer Ingelheim Investigator site 186

    Clermont-Ferrand

  • Boehringer Ingelheim Investigator site 187

    Clichy

  • Boehringer Ingelheim Investigator site 188

    Clisson

  • Boehringer Ingelheim Investigator site 189

    Cognac

  • Boehringer Ingelheim Investigator site 190

    Colombes

  • Boehringer Ingelheim Investigator site 191

    Colombes

  • Boehringer Ingelheim Investigator site 192

    Colombes

  • Boehringer Ingelheim Investigator site 193

    Combles

  • Boehringer Ingelheim Investigator site 194

    Comines

  • Boehringer Ingelheim Investigator site 195

    Condé-sur-l'Escaut

  • Boehringer Ingelheim Investigator site 196

    Condom

  • Boehringer Ingelheim Investigator site 197

    Conflans Ste Honorine

  • Boehringer Ingelheim Investigator site 198

    Conflans Ste Honorine

  • Boehringer Ingelheim Investigator site 199

    Corbehem

  • Boehringer Ingelheim Investigator site 200

    Cornebarrieu

  • Boehringer Ingelheim Investigator site 201

    Coubron

  • Boehringer Ingelheim Investigator site 202

    Courbevoie

  • Boehringer Ingelheim Investigator site 203

    Courbevoie

  • Boehringer Ingelheim Investigator site 204

    Courseulles-sur-Mer

  • Boehringer Ingelheim Investigator site 205

    Coutances

  • Boehringer Ingelheim Investigator site 206

    Creil

  • Boehringer Ingelheim Investigator site 207

    Creully

  • Boehringer Ingelheim Investigator site 208

    Creutzwald

  • Boehringer Ingelheim Investigator site 209

    Croix

  • Boehringer Ingelheim Investigator site 210

    Croix

  • Boehringer Ingelheim Investigator site 211

    Cros-de-Cagnes

  • Boehringer Ingelheim Investigator site 212

    Crosne

  • Boehringer Ingelheim Investigator site 213

    Cugnaux

  • Boehringer Ingelheim Investigator site 214

    Culoz

  • Boehringer Ingelheim Investigator site 215

    Damprichard

  • Boehringer Ingelheim Investigator site 216

    Damvillers

  • Boehringer Ingelheim Investigator site 217

    Danjoutin

  • Boehringer Ingelheim Investigator site 218

    Dax

  • Boehringer Ingelheim Investigator site 219

    Décines-Charpieu

  • Boehringer Ingelheim Investigator site 220

    Diemeringen

  • Boehringer Ingelheim Investigator site 221

    Digne-les-Bains

  • Boehringer Ingelheim Investigator site 222

    Dijon

  • Boehringer Ingelheim Investigator site 223

    Dijon

  • Boehringer Ingelheim Investigator site 224

    Dijon

  • Boehringer Ingelheim Investigator site 225

    Dinan

  • Boehringer Ingelheim Investigator site 226

    Dinard

  • Boehringer Ingelheim Investigator site 227

    Dole

  • Boehringer Ingelheim Investigator site 228

    Domont

  • Boehringer Ingelheim Investigator site 229

    Douai

  • Boehringer Ingelheim Investigator site 230

    Dourdan

  • Boehringer Ingelheim Investigator site 231

    Douvaine

  • Boehringer Ingelheim Investigator site 232

    Douvres-la-Délivrande

  • Boehringer Ingelheim Investigator site 233

    Drancy

  • Boehringer Ingelheim Investigator site 234

    Drancy

  • Boehringer Ingelheim Investigator site 235

    Drap

  • Boehringer Ingelheim Investigator site 236

    Drulingen

  • Boehringer Ingelheim Investigator site 237

    Échirolles

  • Boehringer Ingelheim Investigator site 238

    Échirolles

  • Boehringer Ingelheim Investigator site 239

    Elliant

  • Boehringer Ingelheim Investigator site 240

    Enghien-les-Bains

  • Boehringer Ingelheim Investigator site 241

    Enghien-les-Bains

  • Boehringer Ingelheim Investigator site 242

    Épernay

  • Boehringer Ingelheim Investigator site 243

    Épernon

  • Boehringer Ingelheim Investigator site 244

    Épierre

  • Boehringer Ingelheim Investigator site 245

    Épinal

  • Boehringer Ingelheim Investigator site 246

    Épinay-sur-Orge

  • Boehringer Ingelheim Investigator site 247

    Ermont

  • Boehringer Ingelheim Investigator site 248

    Esquerdes

  • Boehringer Ingelheim Investigator site 249

    Estrablin

  • Boehringer Ingelheim Investigator site 250

    Estrées-Saint-Denis

  • Boehringer Ingelheim Investigator site 251

    Étampes

  • Boehringer Ingelheim Investigator site 252

    Eu

  • Boehringer Ingelheim Investigator site 253

    Eygalières

  • Boehringer Ingelheim Investigator site 254

    Eyragues

  • Boehringer Ingelheim Investigator site 255

    Fabrezan

  • Boehringer Ingelheim Investigator site 256

    Faches-Thumesnil

  • Boehringer Ingelheim Investigator site 257

    Famars

  • Boehringer Ingelheim Investigator site 258

    Fauquembergues

  • Boehringer Ingelheim Investigator site 259

    Fécamp

  • Boehringer Ingelheim Investigator site 260

    Félines

  • Boehringer Ingelheim Investigator site 261

    Figeac

  • Boehringer Ingelheim Investigator site 262

    Firmi

  • Boehringer Ingelheim Investigator site 263

    Firminy

  • Boehringer Ingelheim Investigator site 264

    Fitilieu

  • Boehringer Ingelheim Investigator site 265

    Flayosc

  • Boehringer Ingelheim Investigator site 266

    Fleurance

  • Boehringer Ingelheim Investigator site 267

    Fleury-sur-Orne

  • Boehringer Ingelheim Investigator site 268

    Flize

  • Boehringer Ingelheim Investigator site 269

    Florensac

  • Boehringer Ingelheim Investigator site 270

    Folembray

  • Boehringer Ingelheim Investigator site 271

    Fontaine-lès-Dijon

  • Boehringer Ingelheim Investigator site 272

    Fontaine-lès-Dijon

  • Boehringer Ingelheim Investigator site 273

    Fontenay-le-Comte

  • Boehringer Ingelheim Investigator site 274

    Fontenay-sous-Bois

  • Boehringer Ingelheim Investigator site 275

    Fos-sur-Mer

  • Boehringer Ingelheim Investigator site 276

    Fosses

  • Boehringer Ingelheim Investigator site 277

    Fougères

  • Boehringer Ingelheim Investigator site 278

    Fougères

  • Boehringer Ingelheim Investigator site 279

    Franconville

  • Boehringer Ingelheim Investigator site 280

    Frasne

  • Boehringer Ingelheim Investigator site 281

    Frencq

  • Boehringer Ingelheim Investigator site 282

    Fresnes-sur-Escaut

  • Boehringer Ingelheim Investigator site 283

    Froideconche

  • Boehringer Ingelheim Investigator site 284

    Fruges

  • Boehringer Ingelheim Investigator site 285

    Gagny

  • Boehringer Ingelheim Investigator site 286

    Gallardon

  • Boehringer Ingelheim Investigator site 287

    Garchizy

  • Boehringer Ingelheim Investigator site 288

    Gâvres

  • Boehringer Ingelheim Investigator site 289

    Gennes

  • Boehringer Ingelheim Investigator site 290

    Gentilly

  • Boehringer Ingelheim Investigator site 291

    Giraumont

  • Boehringer Ingelheim Investigator site 292

    Gironcourt-sur-Vraine

  • Boehringer Ingelheim Investigator site 293

    Golbey

  • Boehringer Ingelheim Investigator site 294

    Gondrecourt-le-Château

  • Boehringer Ingelheim Investigator site 295

    Gontaud-de-Nogaret

  • Boehringer Ingelheim Investigator site 296

    Goudelin

  • Boehringer Ingelheim Investigator site 297

    Gouville-sur-Mer

  • Boehringer Ingelheim Investigator site 298

    Grambois

  • Boehringer Ingelheim Investigator site 299

    Gray

  • Boehringer Ingelheim Investigator site 300

    Grenoble

Other trials in France

About this study

Official title: A Descriptive Pharmaco-epidemiological Study of a Hypertensive Patient Population Treated With a Fixed-dose Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg and of Conditions for the Management of Arterial Hypertension

It is a national, retrospective , observational study in hypertensive patients treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg. The primary objective is to assess the control rate (systolic and diastolic blood pressure). Key secondary objectives are to assess the blood pressure reduction after at least 8 weeks of treatment, describe the population treated with this new fixed dose combination

Conditions
Hypertension
Medical subject headings
Hypertension

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of BP Control in Hypertensive Patients

    Percentage of controlled Patients at the Study End.

    Control rate of hypertension in general practice and in cardiology defined as systolic blood pressure (SBP) and diastolic blood pressure (DBP) <140/90 mmHg for unselected hypertensive patients and SBP and DBP <130/80 mmHg for hypertensive patients at high cardiovascular risk (patients with diabetes and patients with impaired renal function) as defined in the recommendations of the French National Health Authority (HAS) 2005 guidelines.

    Measured: Baseline to a minimum of 8 weeks of treatment

Secondary outcomes (5)

  1. Systolic Blood Pressure (SBP) After at Least 8 Weeks of Treatment in Overall Study Population

    Mean SBP measured at the Study End

    Measured: baseline to a minimum of 8 weeks of treatment

  2. Diastolic Blood Pressure (DBP) After at Least 8 Weeks of Treatment in Overall Study Population

    Mean DBP measured at the Study End

    Measured: baseline to a minimum of 8 weeks of treatment

  3. Systolic Blood Pressure (SBP) After at Least 8 Weeks of Treatment in Population at High Cardiovascular Risk

    Mean SBP measured at the Study End

    Measured: baseline to a minimum of 8 weeks of treatment

  4. Diastolic Blood Pressure (DBP) After at Least 8 Weeks of Treatment in Population at High Cardiovascular Risk

    Mean DBP measured at the Study End

    Measured: baseline to a minimum of 8 weeks of treatment

  5. Rate of BP Control by Risk Factor According to the Recommendations ESH/ESC 2007

    The proportion of patients with blood pressure (BP) control, per risk factor. High risk factors determined according to the recommendations of the ESH/ESC 2007.

    Measured: Baseline to a minimum of 8 weeks of treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 May 2009 (estimated)
  2. Study startMay 2009
  3. Primary completionNov 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
2,411 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00909038
Sponsor's protocol ID
502.574
Status last verified
May 2014
First submitted
26 May 2009
Last updated
5 Jun 2014

Questions about this trial

What is this clinical trial studying?

An observational study of Hypertension, run by Boehringer Ingelheim at 915 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 915 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 14 Apr 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of BP Control in Hypertensive Patients (time frame: Baseline to a minimum of 8 weeks of treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00909038.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2014.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in